Prestige Biopharma, a South Korean biopharmaceutical developer, said on Tuesday that the final analysis of phase 3 clinical trial on the anti-cancer biosimilar (biopharmaceutical generic drug) HD201 proved its equivalence to the original drug Herceptin.HD201 is Prestige Biopharma's first biosi
Prestige Biopharma, a Singapore-based biopharmaceutical company with operations in South Korea and the US, has applied to the Australian clinical trial review committee for its phase 1 and 2a clinical trial plan of its new pancreatic cancer drug PBP1510 (ulenistamab).The company speciali
Prestige Biopharma Korea said on Tuesday that it has obtained a domestic patent for the CTHRC1 neutralizing antibody of the drug candidate PBP1710. The patent name is “Novel CTHRC1's specific antibody and use thereof."Following the PAUF (pancreatic adenocarcinoma up-regulated factor) neu